![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intricon Corporation | NASDAQ:IIN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.24 | 24.24 | 24.25 | 0 | 01:00:00 |
Filed by the Registrant |
☒
|
Filed by a party other than the Registrant |
☐
|
☐ |
Preliminary Proxy Statement
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐ |
Definitive Proxy Statement
|
☒ |
Definitive Additional Materials
|
☐ |
Soliciting Material under §240.14a-12
|
☐ |
No fee required.
|
☒ |
Fee paid previously with preliminary materials.
|
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
EV / EBITDA
|
||||||||
2021
|
2022
|
|||||||
Integer Holdings Corporation
|
15.4x
|
12.8x
|
||||||
Nolato AB
|
13.9x
|
12.5x
|
||||||
UFP Technologies, Inc.
|
11.8x
|
8.5x
|
||||||
Maximum
|
15.4x
|
12.8x
|
||||||
75th Percentile
|
14.7x
|
12.7x
|
||||||
Mean
|
13.7x
|
11.3x
|
||||||
Median
|
13.9x
|
12.5x
|
||||||
25th Percentile
|
12.9x
|
10.5x
|
||||||
Minimum
|
11.8x
|
8.5x
|
||||||
The Company at the February 25th Closing Price ($17.42)
|
15.8x
|
10.5x
|
||||||
The Company at the Per Share Merger Consideration ($24.25)
|
23.4x
|
15.6x
|
Marle International SAS(1)(2)(3)
|
IK Investment Partners Limited
|
May 25, 2016
|
-----
|
-----
|
-----
|
|||||
Alcoa, Inc. (Remmele Medical Operations business)(1)(2)(3)
|
LISI SA
|
April 11, 2016
|
-----
|
-----
|
-----
|
|||||
Creganna-Tactx Medical(1)(2)
|
TE Connectivity LTD.
|
February 2, 2016
|
$895
|
-----
|
-----
|
|||||
Lake Region Medical, Inc.(2)
|
Greatbatch, Inc.
|
August 27, 2015
|
$1,727
|
11.6x
|
-----
|
|||||
Precision Engineered Products, LLC(4)
|
NN, Inc.
|
August 17, 2015
|
$615
|
8.9x
|
-----
|
|||||
AdvancedCath Technologies, LLC(1)(2)
|
TE Connectivity LTD.
|
February 18, 2015
|
$190
|
-----
|
-----
|
|||||
Precision Wire Components, LLC(1)(2)(3)
|
Creganna-Tactx Medical
|
October 29, 2014
|
-----
|
-----
|
-----
|
|||||
Symmetry Medical Inc. (OEM Solutions business)(4)
|
Tecomet Inc.
|
August 4, 2014
|
$450
|
9.4x
|
-----
|
|||||
Avalon Laboratories, LLC(1)(2)
|
Nordson Corporation
|
August 4, 2014
|
$180
|
-----
|
-----
|
|||||
Lake Region Medical, Inc.(1)(2)
|
Accellent Inc.
|
February 3, 2014
|
$390
|
-----
|
-----
|
|||||
Maximum
|
28.2x
|
20.0x
|
||||||||
75th Percentile
|
15.6x
|
13.3x
|
||||||||
Mean
|
$573
|
14.0x
|
12.0x
|
|||||||
Median
|
$392
|
13.3x
|
11.4x
|
|||||||
25th Percentile
|
11.2x
|
10.0x
|
||||||||
Minimum
|
7.4x
|
6.9x
|
||||||||
The Company at the February 25th Closing Price ($17.42)
|
$143
|
15.8x
|
10.5x
|
|||||||
The Company at the Per Share Merger Consideration ($24.25)
|
$212
|
23.4x
|
15.6x
|
(1) |
EV/LTM EBITDA data was confidential.
|
(2) |
EV/FTM EBITDA data was confidential.
|
(3) |
Enterprise Value data was confidential.
|
(4) |
EV/FTM EBITDA data was not available.
|
Synergetics USA, Inc.
|
Valeant Pharmaceuticals International, Inc.
|
September 2, 2015
|
$188
|
21.0x
|
19.6x
|
|||||
AdvancedCath Technologies, LLC(1)(2)
|
TE Connectivity LTD.
|
February 18, 2015
|
$190
|
-----
|
-----
|
|||||
FH Orthopedics S.A.S(1)(2)(3)
|
LBO France Gestion SAS
|
October 30, 2014
|
-----
|
-----
|
-----
|
|||||
Avalon Laboratories, LLC(1)(2)
|
Nordson Corporation
|
August 4, 2014
|
$180
|
-----
|
-----
|
|||||
AccessClosure, Inc.(1)(2)
|
Cardinal Health, Inc.
|
April 1, 2014
|
$320
|
-----
|
-----
|
|||||
Maximum
|
28.2x
|
24.4x
|
||||||||
75th Percentile
|
18.0x
|
15.8x
|
||||||||
Mean
|
$326
|
15.9x
|
13.5x
|
|||||||
Median
|
$250
|
15.5x
|
12.8x
|
|||||||
25th Percentile
|
11.9x
|
10.3x
|
||||||||
Minimum
|
9.3x
|
7.7x
|
||||||||
The Company at the February 25th Closing Price ($17.42)
|
$143
|
15.8x
|
10.5x
|
|||||||
The Company at the Per Share Merger Consideration ($24.25)
|
$212
|
23.4x
|
15.6x
|
(1) |
EV/LTM EBITDA data was confidential.
|
(2) |
EV/FTM EBITDA data was confidential.
|
(3) |
Enterprise Value data was confidential.
|
(4) |
EV/FTM EBITDA data was not available.
|
(5) |
EV/LTM EBITDA multiple was greater than 30.0x.
|
Name/Title of Rollover Shareholder
|
Number of
Rollover
Shares
|
Value of Rollover
Shares Based on Per-
Share Merger
Consideration
|
Number of Class A
Units to be Issued for
Rollover Shares
|
Value of Class A
Units to be
Issued for the
Rollover Shares
|
||||||||||||
Scott Longval, President, Chief Executive Officer and a Director
|
20,619
|
$
|
500,011
|
500,011
|
$
|
500,011
|
||||||||||
Michael P. Geraci, Senior Vice President, Sales and Marketing
|
4,124
|
$
|
100,007
|
100,007
|
$
|
100,007
|
||||||||||
Mark Gorder, Director
|
103,093
|
$
|
2,500,005
|
2,500,005
|
$
|
2,500,005
|
||||||||||
Doug Pletcher, Vice President, Medical and Business Development
|
4,124
|
$
|
100,007
|
100,007
|
$
|
100,007
|
||||||||||
Philip I. Smith, Chairman of the Board of Directors
|
4,124
|
$
|
100,007
|
100,007
|
$
|
100,007
|
||||||||||
Total
|
136,084
|
$
|
3,300,037
|
3,300,037
|
$
|
3,300,037
|
1 Year Intricon Chart |
1 Month Intricon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions